Sarfaty, Michal
Rosenberg, Jonathan E.
Article History
First Online: 1 February 2020
Compliance with Ethical Standards
:
: Michal Sarfaty has received compensation for service (Honoraria) from Merck, Novartis and Roche. Jonathan E. Rosenberg has received research funding from Roche/Genentech and Novartis; compensation for service as a consultant from Adicet Bio, Astellas, AstraZeneca, Bayer, BioClin/Rainier Therapeutics, Bristol-Myers Squibb, Eli Lilly, Fortress Biotech, Inovio, Merck, Mirati Therapeutics, EMD-Serono, QED Therapeutics, Roche/Genentech, Sanofi, Seattle Genetics, Sensei Biotherapeutics, Chugai Pharmaceutical, Medscape, Pharmacyclics, and Janssen; owns stock in Merck; has institutional financial interests (trial funding) in Astellas, AstraZeneca, Bayer, Mirati Therapeutics, Roche/Genentech, Seattle Genetics, and OncoGenex; and has received royalties from UpToDate.
: This article does not contain any studies with human or animal subjects performed by any of the authors.